

Paper alert

371 Jonathan Hirst, Peter Norman & David P Rotella

Patent alert

385 Susan Wan

Web alert

393 David Cavalla

The Chemistry of Drug Design and Lead Optimization

Edited by William J Greenlee & Manoj C Desai

395 Manoj C Desai & William J Greenlee

Editorial overview: Transporter proteins in drug disposition and uptake

396 Ajay N Jain

Virtual screening in lead discovery and optimization

404 Marcel Verdonk & Michael J Hartshorn

Structure-guided fragment screening for lead discovery

411 Kenneth M Comess & Mark E Schurdak

Affinity-based screening techniques for enhancing lead discovery

417 Karolina Ersmark, Mats Larhed & Johan Wannberg

Microwave-enhanced medicinal chemistry: A high-speed opportunity for convenient preparation of protease inhibitors

428 David J Pratt, Jane A Endicott & Martin EM Noble

The role of structure in kinase-targeted inhibitor design

437 Juswinder Singh, Leona E Ling, J Scott Sawyer, Wen-Cherng Lee, Faming Zhang & Jonathan M Yingling

Transforming the TGF β pathway: Convergence of distinct lead generation strategies on a novel kinase pharmacophore for T β RI (ALK5)

446 Zhi-Jie Ni & Allan S Wagman

Progress and development of small molecule HCV antivirals

460 Mimi Quan & Joanne Smallheer

The race to an orally active Factor Xa inhibitor: Recent advances

470 Michael S Lajiness, Michal Vieth & Jon Erickson

Molecular properties that influence oral drug-like behavior

478 Ronald J Doll, Paul Kirschmeier & W Robert Bishop

Farnesyltransferase inhibitors as anticancer agents: Critical crossroads

487 Paul J Gilligan & Yu-Wen Li

Corticotropin-releasing factor antagonists: Recent advances and exciting prospects for the treatment of human diseases

498 Jos HM Lange & Chris G Kruse

Recent advances in CB₁ cannabinoid receptor antagonists

507 Nicole A Kratochwil, Walter Huber, Francis Müller, Manfred Kansy & Paul R Gerber

Predicting plasma protein binding of drugs - revisited

513 Hans Matter & Manfred Schudok

Recent advances in the design of matrix metalloprotease inhibitors

536 Jared N Cumming, Ulrich Iserloh & Matthew E Kennedy

Design and development of BACE-1 inhibitors